U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06887036) titled 'Methylene Blue Treatment of Chronic Hepatitis B Virus Infection' on March 14.
Brief Summary: HBV infection is a global public health problem. It is estimated that there are more than 250 million HBV carriers worldwide, of whom approximately 600,000 die each year from HBV-related liver disease. Diagnosis and treatment depend on the stage of infection, the degree of liver inflammation, and the progression of fibrosis. Patients with HBeAg-positive or -negative hepatitis are usually treated with nucleos(-t)ide analogues. This treatment inhibits HBV reverse transcriptase and reduces viral replication, but does not affect HBsAg productio...